CBChokan Baimukhamedov

Chokan Baimukhamedov

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Chokan Baimukhamedov has a total of 109 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Eurasian Consensus of Rheumatologists on the diagnosis and treatment of systemic lupus erythematosus

    by G. A. Togizbaev, Ch. T. Baimukhamedov, B. G. Issayeva, Zh. E. Omarbekova, G. M. Koylubaeva, O. V. Lobanchenko, N. A. Martusevich, K. A. Chizh, S. M. Shukurova, A. A. Haroyan, et al.

    A group of leading rheumatologists from the Commonwealth of Independent States (CIS) countries has prepared clinical guidelines for the diagnosis, treatment, and monitoring of systemic lupus erythematosus. These clinical guidelines are based on the recommendations of the national rheumatology associations of the CIS countries, the international guidelines of the European Alliance of Associations for Rheumatology, and the American College of Rheumatology. These guidelines are intended for a wide range of specialists in the CIS countries, including rheumatologists and general practitioners.

  • Open Access

    Late-onset systemic sclerosis: current concepts, uncertainties, and future practice guidelines

    by Chokan Baimukhamedov, Galiya Аssanova

    Late-onset systemic sclerosis (LOSS) is a clinical phenotype of systemic sclerosis with disease onset at age 60 years or older.

  • Open Access

    Late‐onset rheumatoid arthritis versus elderly‐onset rheumatoid arthritis: understanding the key differences: comment on the article by Lee et al

    by Galymzhan Togizbayev, Chokan Baimukhamedov, Galiya Аssanova, Khilola Mirakhmedova, Maya Goremykina


  • Top Cited Papers
    Open Access

    Late-onset rheumatoid arthritis: clinical features, diagnostic challenges, and treatment approaches

    by Olena Zimba, Chokan Baimukhamedov, Burhan Fatih Kocyigit

    Late-Onset Rheumatoid Arthritis (LORA) is receiving increased clinical attention due to global aging trends. LORA presents distinct diagnostic, clinical, and therapeutic challenges. It often presents with a balanced gender distribution, acute onset, preferential involvement of larger joints, and decreased seropositivity. The diagnostic process is complex due to atypical presentations, comorbidities, and limitations of classification criteria, which insufficiently address the heterogeneity of LORA phenotypes. Patients with LORA often experience age-related geriatric syndromes, including frailty, cognitive decline, and malnutrition, in addition to comorbid cardiovascular disorders, pulmonary involvement, oncologic conditions, and osteoporosis. All these factors confound disease progression and treatment strategies, necessitating careful consideration of polypharmacy and modified drug metabolism. While the treatment principles largely align with those of Younge-Onset Rheumatoid Arthiritis (YORA), LORA management requires individualized approaches. Available evidence suggests that with proper monitoring, disease-modifying anti-rheumatic drugs (DMARDs) are safe and effective for older adults. Glucocorticoids should be minimized due to potential detrimental effects. Despite elevated baseline disease activity and functional deterioration, effectively managed LORA patients may achieve disease control similar to that of younger individuals. This review advocates for age-adjusted diagnostic strategies and patient-centered care models tailored to the needs of older RA patients. Addressing these unmet needs may enhance outcomes and quality of life for the growing population of LORA patients.


  • Open Access

    Global practice guidelines in rheumatology: a cross-sectional altmetric and citation analysis

    by Olena Zimba, Mariusz Korkosz, Fatima Alnaimat, George E. Fragoulis, Marlen Yessirkepov, Chokan Baimukhamedov, Burhan Fatih Kocyigit

    Clinical practice guidelines are instrumental for managing rheumatic diseases, which are often chronic, multifaceted, and require evidence-based diagnostic and therapeutic approaches. This study assessed the societal and academic implications of global rheumatology practice guidelines. A cross-sectional altmetric and citation analysis was conducted to assess the implications of rheumatology practice guidelines. Practice guidelines published in Annals of the Rheumatic Diseases and Arthritis & Rheumatology (2000–2024) were retrieved through PubMed searches. A total of 127 guidelines were included in this study. On April 9, 2025, the Altmetric Attention Score (AAS), Mendeley bookmarking data, and citation metrics from the Scopus and Dimensions databases were recorded for each document. A significant rise in the volume of published guidelines over time was detected (p < 0.001 for the trend). Guidelines in Annals of the Rheumatic Diseases attracted more Scopus citations (median: 320) compared to Arthritis & Rheumatology (median: 145.5; p = 0.046); AAS values did not show a significant difference between the sources (p = 0.168). The analysis demonstrated statistically significant positive correlations between Scopus citation counts and several altmetric indices, including AAS, news outlets, and Facebook mentions, and Mendeley bookmarking counts (all p < 0.001). No correlations recorded for X (Twitter) mentions. This study reveals the implications of global rheumatology practice guidelines in view of their traditional and alternative metrics. To maximize the societal implications, renewed social media strategies are warranted to expand online visibility and academic outreach of global rheumatology practice guidelines.


  • Biologic Therapy in Rheumatology: Analysis of Multidisciplinary Teams' Performance in Kazakhstan

    by Galymzhan Togizbayev, Iran Shametekov, Danagul Maksot, Zhanar Kozhamuratova, Gulsana Alikhan, Danira Ermekbai, Chokan Baimukhamedov


  • Open Access

    Consensus Statement on the Management of Patients With Asymptomatic Hyperuricemia in General Medical Practice

    by Oksana M. Drapkina, Vadim I. Mazurov, Martynov I. Martynov, Evgeny L. Nasonov, Sergey A. Saiganov, Aleksander M. Lila, Roman A. Bashkinov, Irina N. Bobkova, Chokan T. Baimukhamedov, Inna Z. Gaydukova, et al.

    Hyperuricemia is a condition characterized by an increase of serum uric acid level above 360 µmol/L. It is known that high serum uric acid levels are not only the condition for the etiopathogenesis of gout but also an important risk factor for the development and progression of cardiovascular diseases, kidney and liver pathologies, type 2 diabetes, and others. This makes hyperuricemia a relevant issue in general therapeutic practice. Despite extensive evidence on the negative role of hyperuricemia in many internal organ diseases, the management strategy for patients with asymptomatic hyperuricemia in real clinical practice remains a subject of debate. This resolution represents an interdisciplinary consensus of experts from Commonwealth of Independent States, based on current evidence-based medicine data and proprietary registries. The proposed algorithm emphasizes the importance of a personalized approach to the treatment of hyperuricemia, taking into account the severity of comorbid conditions and the level of cardiovascular risk. Step-by-step recommendations are provided for general practitioners, family doctors, and a wide range of specialists in both non-pharmacological and pharmacological urate-lowering therapy. These guidelines aim to improve the quality of medical care for patients at high risk of socially significant diseases occurring together with asymptomatic hyperuricemia.


  • Late-onset Systemic Lupus Erythematosus

    by Prakashini Mruthyunjaya, Sakir Ahmed, Aliya Botabekova, Chokan Baimukhamedov, Olena Zimba

    Systemic lupus erythematosus (SLE) is a multisystem autoimmune rheumatic disease (ARD) that results from the dysregulation of multiple innate and adaptive immune pathways. Late-onset SLE (Lo-SLE) is the term used when the disease is first diagnosed after 50–65 years, though the standard age cut-off remains undefined. Defining “late-onset” as lupus with onset after 50 years is more biologically plausible as this roughly corresponds to the age of menopause. Lo-SLE comprises nearly 20% of all cases of lupus. With advancing age, the female predominance of lupus declines to nearly 4:1 to even 1.1:1. The natural history of the disease varies, with lesser major organ involvement like nephritis but higher damage accrual. The latter is possibly owed to the atypical presentation and hesitation among physicians to diagnose SLE at this age, a diagnostic delay with late treatment initiation may accelerate the damage accrual. Multimorbidity is a central issue in these patients, which includes osteoporosis, sarcopenia, accelerated atherosclerosis in the background of existing dyslipidemia, diabetes mellitus, major depression, hypertension, coronary artery disease and other thrombotic events. With the rising ages of populations worldwide, awareness about late-onset lupus is paramount, especially due to the associated diagnostic delays and higher overlap with Sjogren’s disease. Also, pharmacotherapeutics must be optimized considering factors associated with ageing like declining glomerular filtration rate (GFR), sarcopenia, osteoporosis, and the associated comorbidities. Measures to minimize the exposure to long-term exposure to high-dose steroids are crucial. Beyond this, it is of essence to adopt non-pharmacological interventions as an adjunct to traditional immunosuppression to improve pain, fatigue, depression, and anxiety, improve cardiovascular health and overall better quality of life with favourable long-term outcomes.


  • Late-onset rheumatoid arthritis: Justifying the need for international practice guidelines and classification criteria

    by Chokan Baimukhamedov, Marina Baimukhamedova

    Chokan Baimukhamedov, Marina Baimukhamedova; Late-onset rheumatoid arthritis: justifying the need for international practice guidelines and classification


  • COVID-19 is a trigger of autoimmune rheumatic diseases: a hypothesis tested over time

    by Aisulu Karkabayeva, Khilola Mirakhmedova, Shoira Khusinova, Abdimutalib Mamasaidov, Chokan Baimukhamedov

    We discuss the paper recently published in Rheumatology Internationa. This article reflects on the prevalence of autoimmune rheumatic diseases (ARD) during the COVID-19 pandemic (2020–2023) and compares the same with the pre-pandemic period (2016–2019). We assume that SARS-CoV-2 triggers ARD. This study concerns the 10 million population of Greece, and this work convincingly confirms our hypothesis. Besides, four large cohort studies have demonstrated an increased incidence of autoimmune diseases after surviving COVID-19. Compared to the prepandemic period, all ARD increased, and RA growth in the index study reached a level of more than 20% during the pandemic. A similar trend was observed in our report covering four Central Asian republics, namely Kazakhstan, Kyrgyzstan, Uzbekistan, and Tajikistan. The alarming growth of ARDs due to the consequences of the pandemic can still be predicted for the coming years. Healthcare professionals worldwide should be aware of this hypothesis to plan their COVID-19, long COVID, and ARD diagnostic and therapeutic strategies. We agree with the authors of the index article that more resources and research studies are warranted to optimize the diagnosis and treatment of ARDs in this challenging time.